Dr. Jon Strasser MD
Assistant Professor of Radiation Oncology, THOMAS JEFFERSON UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Jon Strasser, MD, is an Assistant Professor of Radiation Oncology at Thomas Jefferson University and an Attending Physician in Radiology, Oncology, and Radiation Oncology at the Helen F. Graham Cancer Center of the Christiana Care Health System in Delaware. He has interests in surgery, radiology, and radiation oncology. Dr. Strasser is board certified by the American Board of Radiology. He has also done laboratory research on central nervous system malignancies and research on anti-angiogenic agents and tumor growth factors at Brigham and Women's Hospital/ Dana Farber Cancer Center. Dr. Strasser is an expert on new technologies in imaging including MRI, CT, PET, and PET/CT, in new technologies in radiation oncology including intensity-modulated radiation therapy (IMRT), image-guided radiation oncology (IGRT), RapidArc/VMAT, Cyberknife, Tomotherapy, brachytherapy, digital mammography/Tomosynthesis, and on targeted chemotherpeutic agents used in solid and hematological malignancies. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Assistant Professor of Radiation Oncology, THOMAS JEFFERSON UNIVERSITY
- 2005 - Unspecified
- Attending Physician, CHRISTIANA CARE HEALTH SYSTEM, INC.
- 2000 - 2005
- Attending Physician, PARTNERS HEALTHCARE SYSTEM, INC
- 2000 - 2001
- Physician, NEWTON WELLESLEY HOSPITAL CORP
GLG NewsSM Analyses by Jon Strasser
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.
-
May 27, 2008
Look to England's example for ways to solve America's health-care problem | www.sltrib.com
A single payer, national system does work, but may not necessarily be in the best interest of all parties. Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.
-
Watch out Tomo....here comes some competition
November 16, 2007
Varian's New Rapid Arc Delivery | www.varian.com
Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.
-
October 26, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products. Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane, interest), etc. As such, Pfizer, and it's share holders will pay a price for this costly investment. However, Pfizer will survive, and will keep on buying other products to develop and sell
-
Cardiovascular risks no laughing matter
October 26, 2007
More Prominence Urged for Heart Risks in Breast Cancer Treatment | www.medpagetoday.com
Cardiovascular disease in breast cancer is a real risk. As our population is aging, and breast cancer is one of the most comon cancers, it is up to us to minimize risks of treatment related morbidity.
GLG Study Groups with Jon Strasser(?)
| Study Group Name | No. Members |
|---|---|
| Radiologists (US) | 809 |
| Physicians who Treat Diabetes (US) | 638 |
| Diagnostic Radiologists (US) | 520 |
| Radiation Oncologists | 407 |
| Physicians who Treat Acne (US) | 364 |
GLG Live Meetings with Jon Strasser(?)
Jon Strasser has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.